Post-Marketing Surveillance of Lenvima in Korean Patients

Eisai Korea Inc.132 enrolled

Overview

The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.

Study Type

OBSERVATIONAL

Enrollment

132

Conditions

Differentiated Thyroid Carcinoma (DTC)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria: Participants who meet the following criteria will be eligible for inclusion in the study: 1. Participants with approved indication for lenvatinib in Korea 2. Participants who have written consent for use of personal and medical information for the study purpose Exclusion Criteria: Investigators will refer to approved indications and contraindications regarding exclusion criteria

Locations (32)

Eisai Trial Site #18

Outcomes

Primary Outcomes

Number of Participants with Adverse Events, Serious Adverse Events, and Adverse Drug Reactions

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.